- Home
- PSTV vs KZIA Comparison
PSTV vs KZIA Comparison
Compare PSTV & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTV
- KZIA
- Stock Information
- Founded
- PSTV 1996
- KZIA 1994
- Country
- PSTV United States
- KZIA Australia
- Employees
- PSTV N/A
- KZIA N/A
- Industry
- PSTV Medical/Dental Instruments
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- PSTV Health Care
- KZIA Health Care
- Exchange
- PSTV Nasdaq
- KZIA Nasdaq
- Market Cap
- PSTV 7.1M
- KZIA 6.0M
- IPO Year
- PSTV N/A
- KZIA 1999
- Fundamental
- Price
- PSTV $1.20
- KZIA $0.88
- Analyst Decision
- PSTV Strong Buy
- KZIA Strong Buy
- Analyst Count
- PSTV 2
- KZIA 2
- Target Price
- PSTV $13.50
- KZIA $11.50
- AVG Volume (30 Days)
- PSTV 33.2K
- KZIA 5.5M
- Earning Date
- PSTV 03-04-2025
- KZIA 03-26-2025
- Dividend Yield
- PSTV N/A
- KZIA N/A
- EPS Growth
- PSTV N/A
- KZIA N/A
- EPS
- PSTV N/A
- KZIA N/A
- Revenue
- PSTV $5,725,000.00
- KZIA $1,655,324.00
- Revenue This Year
- PSTV $32.12
- KZIA N/A
- Revenue Next Year
- PSTV N/A
- KZIA N/A
- P/E Ratio
- PSTV N/A
- KZIA N/A
- Revenue Growth
- PSTV 52.63
- KZIA 248000.00
- 52 Week Low
- PSTV $0.93
- KZIA $0.85
- 52 Week High
- PSTV $2.67
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- PSTV 48.71
- KZIA 29.00
- Support Level
- PSTV $1.18
- KZIA $0.90
- Resistance Level
- PSTV $1.30
- KZIA $1.60
- Average True Range (ATR)
- PSTV 0.09
- KZIA 0.14
- MACD
- PSTV -0.00
- KZIA 0.02
- Stochastic Oscillator
- PSTV 45.42
- KZIA 4.00
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.